Inovio Pharmaceuticals Inc (INO)

8.12
NASDAQ : Health Care
Prev Close 8.12
Day Low/High 0.00 / 0.00
52 Wk Low/High 5.83 / 11.00
Avg Volume 1.57M
Exchange NASDAQ
Shares Outstanding 74.63M
Market Cap 625.37M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stocks Under $10 Weekly Summary

We initiated 2 new positions in a week dominated by political events.

Adding to Inovio Pharmaceuticals

INO has reached our bid levels.

Initiating Position in Biotech; Update on ACRX

We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.

Inovio Pharmaceuticals: Cramer's Top Takeaways

Inovio Pharmaceuticals: Cramer's Top Takeaways

Jim Cramer takes a closer look at Inovio Pharmaceuticals, a small biotech developing DNA-based immunotherapies to treat cancer.

Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)

Stay Focused, People!: Cramer's 'Mad Money' Recap (Thursday, 6/8/17)

Jim Cramer says the story is less about Comey vs. Trump than it is about Nvidia vs. Nordstrom.

Biotech Movers: NewLink, Inovio, Juno

Biotech Movers: NewLink, Inovio, Juno

NewLink Genetics, Inovio Pharmaceuticals and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

Inovio Begins Phase 3 Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-Cancer 

FDA removes clinical hold on phase 3; Inovio to immediately begin recruiting subjects

Inovio Zika Vaccine Prevents Persistence Of Virus And Damage In Male Reproductive Tract In Pre-Clinical Study

Zika DNA vaccine may protect against sexual transmission

These Stocks Have Changed Direction

These Stocks Have Changed Direction

Finding bullish and bearish reversals in the market.

Inovio Announces Clinical Trial Collaboration To Evaluate A Novel T-cell Immunotherapy In Combination With A PD-L1 Checkpoint Inhibitor

Phase 1b/2 clinical trial to evaluate combination of Inovio's T cell immunotherapy INO-5401 and Genentech's PD-L1 checkpoint inhibitor atezolizumab

Biotech Movers: Inovio, Neurocrine, Alnylam

Biotech Movers: Inovio, Neurocrine, Alnylam

Inovio Pharmaceuticals, Neurocrine Biosciences and Alnylam Pharmaceuticals were among the biotech movers in premarket trading on Wednesday.

Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates In A Clinical Study

Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human study

Inovio Provides Update On MedImmune Launch Of Combination Trial For HPV-associated Head & Neck Cancer

Phase 1b/2a study combines MedImmune's MEDI0457 (INO-3112), a DNA-based immunotherapy targeting HPV-associated cancer, and durvalumab, an immune checkpoint (PD-L1) inhibitor

Biotech Movers: Horizon, OncoMed, Inovio

Biotech Movers: Horizon, OncoMed, Inovio

Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.

Inovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement For Glioblastoma Combination Therapy

Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer

Inovio Stock Rises on Positive Results From Ebola Vaccine Tests

Inovio Stock Rises on Positive Results From Ebola Vaccine Tests

The vaccine study showed that 95% of subjects generated an Ebola-specific antibody immune response.

Inovio And Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP's Ability to Induce Remission Of HIV Infection And End Lifetime Of Drug Therapy

Grant will fund therapeutic clinical studies testing PENNVAX-GP with INO-9012 (an IL-12 immune activator) alone and with the addition of a PD-1 checkpoint inhibitor

First Week Of INO November 17th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 17th expiration.

George Bickerstaff Elected To Inovio's Board Of Directors

Former Novartis CFO brings finance, fundraising and M&A experience to Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.